Elixir Medical Corporation Licenses Myolimus(TM) From Novartis Pharma AG for Site-Specific Drug...

Posted on: Friday, 10 October 2008, 09:00 CDT Elixir Medical Corporation announced today that the company entered into a co-exclusive worldwide license agreement with Novartis Pharma AG granting Elixir the rights to utilize the drug Myolimus with Elixir's vascular and other site-specific drug-delivery applications. In addition, Elixir has an exclusive worldwide license for use of Myolimus in fully biodegradable stents. "Elixir is committed to be a leader in the drug eluting stent market through the efficient development of a broad and innovative portfolio of DES products to better address physician and patient needs," said Motasim Sirhan, chief executive officer of Elixir Medical Corporation. "The license agreement with Novartis Pharma AG for Myolimus enhances our capabilities to develop innovative product platforms for our... [read full story]